Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences expects BaroFold Inc to have "significant" impact on revenues in 2018

BaroFold, among other assets, has developed PreEMT technology, which improves the quality of manufacturing biopharma products
Pressure BioSciences expects BaroFold Inc to have "significant" impact on revenues in 2018
Pressure BioSciences has developed unique and superior pressure cycling technology (PCT) to prepare biological lab samples

Pressure BioSciences Inc (OTCMKTS:PBIO) says its acquisition of all assets of BaroFold Inc is expected to enhance revenues and will increase its IP (intellectual property) portfolio.

BaroFold, among other assets, has developed PreEMT technology, which improves the quality of manufacturing  biopharma products and decreases manufacturing costs (by as much as US$2-10mln per year per commercial biologic drug), the firm said.

Pressure BioSciences has developed unique and superior pressure cycling technology (PCT) to prepare biological lab samples.

"This acquisition will significantly increase PBI's IP estate in high-pressure technologies with the addition of eight issued and several pending patents," said Alexander Lazarev, vice-president of R&D for PBI.

"These patents give us freedom to operate in several important areas for biologics research and manufacturing: protein folding, re-folding and disaggregation.

"They also provide us the right to grant licenses to third parties to practice the PreEMT and other technologies in both research laboratories and in biopharmaceutical manufacturing, the latter being a very large and rapidly growing field."

Dr Nathan Lawrence, of Pressure BioSciences, added: "Importantly, our existing high-pressure equipment is well-suited to the performance of the R&D and process development studies needed for the development of these biopharmaceutical manufacturing applications and markets.

"In fact, it will quickly become evident that our new, award-winning Barocycler 2320EXT high-pressure instrument was designed with technologies like PreEMT bench scale R&D in mind.

"With our worldwide customer base, supported by our expanded sales and marketing capabilities and our growing equipment and consumables product lines, we believe the newly-acquired BaroFold IP will have a significant impact on our revenues in 2018 and beyond."

Pressure BioSciences shares are down 4.50% to US$3.82 in New York.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

1527682514_angel-delight.jpg
May 30 2018
The latest fundraiser underscores the fact the life sciences business is well supported in the City
1528305384_Untitled-design-(3).jpg
June 07 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
myLotus kit
August 06 2018
The expansion drive is targeting an estimated 2.3mln women per year in the areas of Hebei, Shanghai, Beijing, Shangdong, Henan and Liaoning

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use